Skip to content
Search

Latest Stories

Top Stories

Cuts to science research funding cut American lives short − federal support is essential for medical breakthroughs

Cuts to science research funding cut American lives short − federal support is essential for medical breakthroughs

A stethoscope and medical charts.

Getty Images, krisanapong detraphiphat

Nearly every modern medical treatment can be traced to research funded by the National Institutes of Health: from over-the-counter and prescription medications that treat high cholesterol and pain to protection from infectious diseases such as polio and smallpox.

The remarkable successes of the decades-old partnership between biomedical research institutions and the federal government are so intertwined with daily life that it’s easy to take them for granted.


However, the scientific work driving these medical advances and breakthroughs is in jeopardy. Federal agencies such as the National Institutes of Health and the National Science Foundation are terminating hundreds of active research grants under the current administration’s direction. The administration has also proposed a dramatic reduction in federal support of the critical infrastructure that keeps labs open and running. Numerous scientists and health professionals have noted that changes will have far-reaching, harmful outcomes for the health and well-being of the American people.

The negative consequences of defunding U.S. biomedical research can be difficult to recognize. Most breakthroughs, from the basic science discoveries that reveal the causes of diseases to the development of effective treatments and cures, can take years. Real-time progress can be hard to measure.

Person in white coat standing before a fume hood, back to cameraMedical breakthroughs are built on years of painstaking research.Scott Olson/Getty Image

As biomedical researchers studying infectious diseases, viruses and immunology, we and our colleagues see this firsthand in our own work. Thousands of ongoing national and international projects dedicated to uncovering the causes of life-threatening diseases and developing new treatments to improve and save lives are supported by federal agencies such as the NIH and NSF.

Sign up for The Fulcrum newsletter

Considering a few of the breakthroughs made possible through U.S. federal support can help illustrate not only the significant inroads biomedical research has made for preventing, treating and curing human maladies, but what all Americans stand to lose if the U.S. reduces its investment in these endeavors.

A cure for cancer

The hope and dream of curing cancer unites many scientists, health professionals and affected families across the U.S. After decades of ongoing NIH-supported research, scientists have made significant progress in realizing this goal.

The National Cancer Institute of the NIH is the world’s largest funder of cancer research. This investment has led to advances in cancer treatment and prevention that helped reduce the overall U.S. cancer death rate by 33% from 1991 to 2021.

Basic science research on what causes cancer has led to new strategies to harness a patient’s own immune system to eliminate tumors. For example, all 12 patients in a 2022 clinical trial testing one type of immunotherapy had their rectal cancer completely disappear, without remission or adverse effects.

- YouTubeyoutu.be

Another example of progress is the 2024 results of an ongoing clinical trial of a targeted therapy for lung cancer, showing an 84% reduction in the risk of disease progression or death. Similarly, in a study of women who were immunized against the human papillomavirus at age 12 or 13, none developed the disease later. Since the widespread adoption of HPV vaccination, cervical cancer deaths have dropped 62%.

Despite these incredible successes, there is still a long way to go. In 2024, over 2 million people in the U.S. were estimated to be newly diagnosed with cancer, and 611,720 were expected to die from the disease.

Without sustained federal support for cancer research, progress toward curing cancer and reducing its death rate will stall.

Autoimmune and neurodegenerative diseases

Nearly every family is touched in some way by autoimmune and neurodegenerative diseases. Government-funded research has enabled major advances to combat conditions such as rheumatoid arthritis, multiple sclerosis, Parkinson’s and Alzheimer’s disease.

For example, approximately 1 in 5 Americans have arthritis, an autoimmune disease that causes joint swelling and stiffness. A leading cause of disability and economic costs in the U.S., there is no cure for arthritis. But new drugs in development are able to significantly improve symptoms and slow or prevent disease progression.

Researchers are also gaining insight into what causes multiple sclerosis, an autoimmune disease where the immune system attacks the protective covering of nerves and can result in paralysis. Scientists recently found a link between multiple sclerosis and Epstein-Barr virus, a pathogen estimated to infect over 90% of adults around the world. While multiple sclerosis is currently incurable, identifying its underlying cause can provide new avenues for prevention and treatment.

Former president Barack Obama standing beside a screen reading 'BRAIN INITIATIVE' at a press conferenceThe NIH’s BRAIN Initiative has invested more than $3 billion in neuroscience research since it began in 2013.Mandel Ngan/AFP via Getty Images

Alzheimer’s disease causes irreversible nerve damage and is the leading cause of dementia. In 2024, 6.9 million Americans ages 65 and older were living with Alzheimer’s. Most treatments address cognitive and behavioral symptoms. However, two new drugs developed with NIH-supported research and clinical trials were approved in July 2023 and July 2024 to treat early-stage Alzheimer’s. Federal funding is also supporting the development of blood tests for earlier detection of the disease.

None of these breakthroughs are a cure. But they represent important steps forward on the path toward ultimately reducing or eliminating these devastating ailments. Lack of funding will slow or block further progress, leading to the continued rise of the incidence and severity of these conditions.

Infectious diseases and the next pandemic

The world’s capacity to combat infectious disease will also be weakened by cuts to U.S. federal support of biomedical research.

Over the past 50 years, medical and public health advances have led to the eradication of smallpox globally and the elimination of polio in the U.S. HIV/AIDS, once a death sentence, is now a disease that can be managed with medication. Moreover, a new version of treatments called preexposure prophylaxis, or PrEP, offers complete protection against HIV transmission when taken only twice per year.

Similarly, the COVID-19 pandemic highlights the critical role biomedical research plays in responding to public health threats. Increased federal support of science during this time allowed the United States to emerge with new drugs, vaccine platforms with the potential to treat a variety of chronic diseases, and insights on how to effectively detect and respond to pandemic threats.

The ongoing avian influenza outbreak and its spillover into American dairy herds and poultry farms is another pandemic threat looming on the horizon. Rather than build upon infrastructure for outbreak surveillance and preparedness, grants that would allow scientists to better understand long COVID-19, vaccines and other pandemic-related research are being cut. Decreased funding of biomedical research will hamper the U.S.’s ability to respond to the next pandemic, putting everyone at risk.

Person in white coat sitting at desk with laptop in a lab, with shelves of labeled bottles and other research instrumentsResearch across the country has ground to a halt as grants remain in limbo or have been terminated altogether.Scott Olson/Getty Images

Losses from defunding biomedical research

The National Institutes of Health contributed over $100 billion to support research that ultimately led to the development of all new drugs approved from 2010 to 2016 alone. Over 90% of this funding was for basic research into understanding the causes of disease that provides the foundation for new treatments.

Under the new directive to eliminate projects that support or use terms associated with diversity, equity and inclusion, the NIH and other federal agencies have made deep cuts to biomedical research that will directly affect patient lives.

Already, nearly 41% of Americans will be diagnosed with cancer at some point in their lifetime, and nearly 11% with Alzheimer’s. About 1 in 5 Americans will die from heart disease, and nearly 1.4 million will be rushed to an emergency room due to pneumonia from an infectious disease.

Defunding biomedical research will result in a cascade of effects. There will likely be fewer clinical trials, fewer new treatments and fewer lifesaving drugs. Labs will likely shut down, jobs will be lost, and the process of discovery will stall. The U.S.’s health care system, economy and standing as the world’s leader in scientific innovation will likely decline.

Moreover, when the pipelines of scientific progress are turned off, they will not so easily be turned back on. These consequences will affect all Americans and the rest of the world for decades.

University shortfalls directly resulting from cuts to research support will dramatically reduce the capacity of American institutions to educate and provide opportunities for the next generation. Funding cuts have led to the shuttering or heavy reduction of training programs for future scientists.

Graduate students and postdoctoral trainees are the lifeblood of biomedical research. Supporting these young people committed to public service through research and health care is also an investment in medical advancements and public health. But the uncertainty and instability resulting from the divestment of federally funded programs will likely severely deplete the biomedical workforce, crippling the United States’ ability to deliver future biomedical breakthroughs.

By cutting biomedical research funding, Americans and the rest of the world stand to lose new cures, new treatments and an entire generation of researchers.

Cuts to science research funding cut American lives short − federal support is essential for medical breakthroughs was originally published in The Conversation and shared with permission.

Deborah Fuller is a Professor of Microbiology at the School of Medicine of the University of Washington.

Patrick Mitchell is an Assistant Professor of Microbiology at the School of Medicine of the University of Washington.

Read More

House passes 1,100-page spending and tax bill, raising debt by up to $4 trillion

US Capitol

Roberto Schmidt/AFP via Getty Images

House passes 1,100-page spending and tax bill, raising debt by up to $4 trillion

Early Thursday morning the House passed H.R. 1: One Big Beautiful Bill Act — yes, that’s it’s official title — a 1,100+ page bill with large cuts to both spending and taxes. We know the big picture but little about the details because it hasn’t been available for long enough for anyone to actually read it.

This is the “reconciliation” bill, the first signature legislation moved by Republicans in Congress and President Trump. This bill has special rules that make it immune to the Senate filibuster, so it can pass the Senate if a simple majority vote for it.

Keep ReadingShow less
How the Trump Administration Is Weakening the Enforcement of Fair Housing Laws

Kennell Staten filed a discrimination complaint with the Department of Housing and Urban Development after he was denied housing. His complaint was rejected.

Bryan Birks for ProPublica

How the Trump Administration Is Weakening the Enforcement of Fair Housing Laws

Kennell Staten saw Walker Courts as his best path out of homelessness, he said. The complex had some of the only subsidized apartments he knew of in his adopted hometown of Jonesboro, Arkansas, so he applied to live there again and again. But while other people seemed to sail through the leasing process, his applications went nowhere. Staten thought he knew why: He is gay. The property manager had made her feelings about that clear to him, he said. “She said I was too flamboyant,” he remembered, “that it’s a whole bunch of older people staying there and they would feel uncomfortable seeing me coming outside with a dress or skirt on.”

So Staten filed a complaint with the U.S. Department of Housing and Urban Development in February. It was the type of complaint that HUD used to take seriously. The agency has devoted itself to rooting out prejudice in the housing market since the Fair Housing Act was signed into law in 1968, one week after the assassination of Martin Luther King Jr. And, following a 2020 Supreme Court rulingthat declared that civil rights protections bar unequal treatment because of someone’s sexual orientation or gender identity, HUD considered it illegal to discriminate in housing on those grounds.

Keep ReadingShow less
Just the Facts: What Is a National Emergency?

U.S. President Donald Trump signs an executive order in the Oval Office at the White House on April 23, 2025 in Washington, DC.

Getty Images, Chip Somodevilla

Just the Facts: What Is a National Emergency?

The Fulcrum strives to approach news stories with an open mind and skepticism, striving to present our readers with a broad spectrum of viewpoints through diligent research and critical thinking. As best we can, we remove personal bias from our reporting and seek a variety of perspectives in both our news gathering and selection of opinion pieces. However, before our readers can analyze varying viewpoints, they must have the facts.

Has President Trump issued several executive orders based on national emergency declarations, and if so, which ones are they?

Keep ReadingShow less
The Hidden Moral Cost of America’s Tariff Crisis

Small business owner attaching permanent close sign on the shop door.

Getty Images, Kannika Paison

The Hidden Moral Cost of America’s Tariff Crisis

In the spring of 2025, as American families struggle with unprecedented consumer costs, we find ourselves at a point of "moral reckoning." The latest data from the Yale Budget Lab reveals that tariff policies have driven consumer prices up by 2.9% in the short term. In comparison, the Penn Wharton Budget Model projects a staggering 6% reduction in long-term GDP and a 5% decline in wages. But these numbers, stark as they are, tell only part of the story.

The actual narrative is one of moral choice and democratic values. Eddie Glaude describes this way in his book “Democracy in Black”: Our economic policies must be viewed through the lens of ethical significance—not just market efficiency. When we examine the tariff regime's impact on American communities, we see economic data points and a fundamental challenge to our democratic principles of equity and justice.

Keep ReadingShow less